Hemab Therapeutics director reports warrant holdings

Hemab Therapeutics Holdings, Inc. director and officer Benny Sorensen filed an initial ownership report listing several warrant positions on the company’s common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Hemab Therapeutics Holdings, Inc. director and officer Benny Sorensen filed an initial ownership report listing several warrant positions on the company’s common stock. These include warrants exercisable at $6.00 for 980,782 underlying shares expiring on January 28, 2036 and warrants at $7.07 for 405,658 shares expiring on August 13, 2033.

Additional holdings are warrants at an exercise price of $2.16 for 251,922 underlying shares expiring on March 20, 2032 and warrants at $6.08 for 76,824 shares expiring on February 1, 2031. Footnotes state one grant from 2021 and one from 2022 are fully vested, while grants from 2023 and 2026 vest over four years with 25% cliff vesting and the remainder in equal monthly installments.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Sorensen Benny

Role See Remarks

Type	Security	Shares	Price	Value
holding	Warrants (Right to Buy)	--	--	--
holding	Warrants (Right to Buy)	--	--	--
holding	Warrants (Right to Buy)	--	--	--
holding	Warrants (Right to Buy)	--	--	--

Holdings After Transaction: Warrants (Right to Buy) — 1,715,186 contracts (Direct)

Footnotes (4)

F1. The warrant was granted on February 2, 2021 and is fully vested.
F2. The warrant was granted on March 21, 2022 and is fully vested.
F3. The warrant was granted on August 14, 2023. The shares underlying the warrant vest over four years, with 25% of the shares having vested on March 1, 2024 and the remaining shares vesting in equal monthly installments thereafter.
F4. The warrant was granted on January 29, 2026. The shares underlying the warrant vest over four years, with 25% of the shares vesting on January 1, 2027 and the remaining shares vesting in equal monthly installments thereafter.

Key Figures

Warrant exercise price: $6.00 per share Underlying shares: 980,782 shares Warrant exercise price: $7.07 per share +5 more

8 metrics

Warrant exercise price $6.00 per share Warrants expiring January 28, 2036; 980,782 underlying shares

Underlying shares 980,782 shares Common stock underlying $6.00 exercise price warrants, direct ownership

Warrant exercise price $7.07 per share Warrants expiring August 13, 2033; 405,658 underlying shares

Underlying shares 405,658 shares Common stock underlying $7.07 exercise price warrants, direct ownership

Warrant exercise price $2.16 per share Warrants expiring March 20, 2032; 251,922 underlying shares

Underlying shares 251,922 shares Common stock underlying $2.16 exercise price warrants, direct ownership

Warrant exercise price $6.08 per share Warrants expiring February 1, 2031; 76,824 underlying shares

Underlying shares 76,824 shares Common stock underlying $6.08 exercise price warrants, direct ownership

Key Terms

Warrants (Right to Buy), exercise price, expiration date, fully vested, +1 more

5 terms

Warrants (Right to Buy) financial

"security_title: Warrants (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 6.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-01-28T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

fully vested financial

"The warrant was granted on February 2, 2021 and is fully vested."

vesting in equal monthly installments financial

"the remaining shares vesting in equal monthly installments thereafter."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Hemab Therapeutics (COAG) director Benny Sorensen report on this Form 3?

Benny Sorensen reports initial holdings of several warrants on Hemab Therapeutics common stock. These positions give rights to buy shares at fixed exercise prices before stated expiration dates, with some grants fully vested and others vesting over four years.

What are the main warrant positions reported by Benny Sorensen at Hemab Therapeutics (COAG)?

Sorensen reports warrants with an exercise price of $6.00 covering 980,782 underlying common shares and warrants at $7.07 covering 405,658 shares. He also holds warrants at $2.16 for 251,922 shares and $6.08 for 76,824 shares, each with specific expiration dates.

When do Benny Sorensen’s reported Hemab Therapeutics (COAG) warrants expire?

The reported warrants expire on several future dates: January 28, 2036 for the $6.00 series, August 13, 2033 for the $7.07 series, March 20, 2032 for the $2.16 series, and February 1, 2031 for the $6.08 series, as disclosed in the filing.

How do the vesting terms work for Benny Sorensen’s Hemab Therapeutics (COAG) warrants?

Footnotes state the 2021 and 2022 warrant grants are fully vested. The 2023 grant vests over four years, with 25% vested on March 1, 2024 and the rest vesting in equal monthly installments. The 2026 grant follows a similar four-year schedule starting January 1, 2027.

Does this Hemab Therapeutics (COAG) Form 3 show any insider buying or selling activity?

The Form 3 lists warrant holdings and their terms but does not show buy or sell transactions. Transaction codes are marked as unknown, and the transactions are categorized as holdings, reflecting positions rather than recent market trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/30/2026 - 06:17 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sorensen Benny

(Last)

(First)

(Middle)

C/O HEMAB THERAPEUTICS HOLDINGS, INC.

101 MAIN STREET, SUITE 1220

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/30/2026

3. Issuer Name and Ticker or Trading Symbol
Hemab Therapeutics Holdings, Inc. [ COAG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Warrants (Right to Buy)	⁽¹⁾	02/01/2031	Common Stock	76,824	$6.08	D
Warrants (Right to Buy)	⁽²⁾	03/20/2032	Common Stock	251,922	$2.16	D
Warrants (Right to Buy)	⁽³⁾	08/13/2033	Common Stock	405,658	$7.07	D
Warrants (Right to Buy)	⁽⁴⁾	01/28/2036	Common Stock	980,782	$6	D

Explanation of Responses:

1. The warrant was granted on February 2, 2021 and is fully vested.

2. The warrant was granted on March 21, 2022 and is fully vested.

3. The warrant was granted on August 14, 2023. The shares underlying the warrant vest over four years, with 25% of the shares having vested on March 1, 2024 and the remaining shares vesting in equal monthly installments thereafter.

4. The warrant was granted on January 29, 2026. The shares underlying the warrant vest over four years, with 25% of the shares vesting on January 1, 2027 and the remaining shares vesting in equal monthly installments thereafter.

Remarks:

President and Chief Executive Officer 24.1 Power of Attorney

	/s/ Mads Nikolaj Behrndt-Eriksen, as Attorney-in-Fact	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR